Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study) - Université de Reims Champagne-Ardenne Access content directly
Journal Articles BMJ open respiratory research Year : 2023

Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study)

Caroline Fabry-Vendrand
  • Function : Author
Nolwenn Poccardi
  • Function : Author
Gabriel Thabut
  • Function : Author
Caroline Eteve Pitsaer
  • Function : Author
Adrien Coriat
  • Function : Author
Charlotte Renaudat
  • Function : Author
Andrew Maguire
Thomas Pinto
  • Function : Author

Abstract

Introduction From 2018 single inhaler triple therapy (SITT) became available in France to treat moderate-to-severe chronic obstructive pulmonary disease (COPD). Given its simplified inhaler use compared with multiple inhaler triple therapy (MITT), this therapeutic option has the potential to offer benefit in terms of improved persistence and adherence. Given the lack of real-world evidence of the effectiveness of triple therapy, this study was designed to evaluate the use of MITT and SITT in France and compare persistence. Methods A retrospective cohort study was performed. Patients with COPD who initiated triple therapy between 1 July 2017 and 31 December 2019 were included from The Health Improvement Network, a large electronic medical database in France, which includes pharmacy data. A 60-day treatment gap defined discontinuation and thereby persistence. Results A total of 3134 patients initiated triple therapy for COPD in the study period, among them 485 with SITT. In 2019, the rate of use of SITT was 28.2%. The mean age (67.3 years) and sex (44.2% female) of patients initiating triple therapy was similar between MITT and SITT, and most patients had escalated from dual therapy (84.1%). However, SITT was more frequently initiated by a pulmonologist (59.8%) and a higher prevalence of comorbid asthma was observed for SITT (47.0% vs 37.9%). Persistence was assessed among patients who did not discontinue after a single dispensation of triple therapy (n=1674). Median persistence was 181 days for SITT and 135 days for MITT, and the covariate-adjusted HR for persistence was 1.47 (p<0.001) and the estimated persistence at 1 year was 33% for SITT compared with 18% for MITT. Discussion This study suggests that persistence was higher for the patients treated with SITT compared with MITT in France. Moreover, most patients initiated with triple therapy were previously treated with dual therapy and had exacerbations in the previous year.
Fichier principal
Vignette du fichier
GaetanDeslee_BMJOpenRespRes_2023.pdf (449.32 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04179123 , version 1 (09-08-2023)

Identifiers

Cite

Gaétan Deslee, Caroline Fabry-Vendrand, Nolwenn Poccardi, Gabriel Thabut, Caroline Eteve Pitsaer, et al.. Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study). BMJ open respiratory research, 2023, 10 (1), pp.e001585. ⟨10.1136/bmjresp-2022-001585⟩. ⟨hal-04179123⟩

Collections

URCA P3CELL
22 View
21 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More